Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid is a synthetic small molecule belonging to the phenylpyridine class of organic compounds. It has been studied primarily as an experimental research tool and is not approved for clinical use. The compound acts as a potent inhibitor of serine/threonine-protein kinase Sgk1 (SGK1), with reported IC50 values in the nanomolar range. SGK1 is involved in various cellular processes including ion transport and cell survival pathways. In preclinical studies, inhibition of SGK1 by this compound has shown effects such as modulation of pain behavior and interference with protein-protein interactions relevant to disease models. There are no known brand names or marketed formulations for this substance; it is used mainly in laboratory research settings[2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid.